Your browser doesn't support javascript.
loading
Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis.
Takaoka, Minoru; Zhao, Xiaohui; Lim, Hwee Ying; Magnussen, Costan G; Ang, Owen; Suffee, Nadine; Schrank, Patricia R; Ong, Wei Siong; Tsiantoulas, Dimitrios; Sommer, Felix; Mohanta, Sarajo K; Harrison, James; Meng, Yaxing; Laurans, Ludivine; Wu, Feitong; Lu, Yuning; Masters, Leanne; Newland, Stephen A; Denti, Laura; Hong, Mingyang; Chajadine, Mouna; Juonala, Markus; Koskinen, Juhani S; Kähönen, Mika; Pahkala, Katja; Rovio, Suvi P; Mykkänen, Juha; Thomson, Russell; Kaisho, Tsuneyasu; Habenicht, Andreas J R; Clement, Marc; Tedgui, Alain; Ait-Oufella, Hafid; Zhao, Tian X; Nus, Meritxell; Ruhrberg, Christiana; Taleb, Soraya; Williams, Jesse W; Raitakari, Olli T; Angeli, Véronique; Mallat, Ziad.
Afiliação
  • Takaoka M; Department of Medicine, Section of CardioRespiratory Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge, UK.
  • Zhao X; Department of Medicine, Section of CardioRespiratory Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge, UK.
  • Lim HY; Immunology Translational Research Programme, Yong Loo Lin School of Medicine, Department of Microbiology and Immunology, National University of Singapore, Singapore, Singapore.
  • Magnussen CG; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.
  • Ang O; Research Centre of Applied and Preventive Cardiovascular Medicine; University of Turku, Turku, Finland.
  • Suffee N; Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
  • Schrank PR; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Ong WS; Immunology Translational Research Programme, Yong Loo Lin School of Medicine, Department of Microbiology and Immunology, National University of Singapore, Singapore, Singapore.
  • Tsiantoulas D; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.
  • Sommer F; Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, U970, PARCC, Paris, France.
  • Mohanta SK; Department of Integrative Biology & Physiology, Center for Immunology, University of Minnesota, Minneapolis, MN, USA.
  • Harrison J; Immunology Translational Research Programme, Yong Loo Lin School of Medicine, Department of Microbiology and Immunology, National University of Singapore, Singapore, Singapore.
  • Meng Y; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.
  • Laurans L; Department of Medicine, Section of CardioRespiratory Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge, UK.
  • Wu F; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Lu Y; Institute of Clinical Molecular Biology, University of Kiel and University Hospital Schleswig Holstein (UKSH), Kiel, Germany.
  • Masters L; Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität München (LMU), Munich, Germany.
  • Newland SA; Department of Medicine, Section of CardioRespiratory Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge, UK.
  • Denti L; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Hong M; Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, U970, PARCC, Paris, France.
  • Chajadine M; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Juonala M; Department of Medicine, Section of CardioRespiratory Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge, UK.
  • Koskinen JS; Department of Medicine, Section of CardioRespiratory Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge, UK.
  • Kähönen M; Department of Medicine, Section of CardioRespiratory Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge, UK.
  • Pahkala K; Institute of Ophthalmology, University College London, London, UK.
  • Rovio SP; Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität München (LMU), Munich, Germany.
  • Mykkänen J; Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, U970, PARCC, Paris, France.
  • Thomson R; Department of Medicine, University of Turku, Turku, Finland.
  • Kaisho T; Division of Medicine, Turku University Hospital, Turku, Finland.
  • Habenicht AJR; Research Centre of Applied and Preventive Cardiovascular Medicine; University of Turku, Turku, Finland.
  • Clement M; Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
  • Tedgui A; Division of Medicine, Turku University Hospital, Turku, Finland.
  • Ait-Oufella H; Department of Medicine, Satakunta Central Hospital, Pori, Finland.
  • Zhao TX; Department of Clinical Physiology, University of Tampere, Tampere, Finland.
  • Nus M; Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.
  • Ruhrberg C; Finnish Cardiovascular Research Center Tampere, University of Tampere, Tampere, Finland.
  • Taleb S; Research Centre of Applied and Preventive Cardiovascular Medicine; University of Turku, Turku, Finland.
  • Williams JW; Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
  • Raitakari OT; Research Centre of Applied and Preventive Cardiovascular Medicine; University of Turku, Turku, Finland.
  • Angeli V; Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.
  • Mallat Z; Research Centre of Applied and Preventive Cardiovascular Medicine; University of Turku, Turku, Finland.
Nature ; 634(8033): 457-465, 2024 Oct.
Article em En | MEDLINE | ID: mdl-39231480
ABSTRACT
Hyperlipidaemia is a major risk factor of atherosclerotic cardiovascular disease (ASCVD). Risk of cardiovascular events depends on cumulative lifetime exposure to low-density lipoprotein cholesterol (LDL-C) and, independently, on the time course of exposure to LDL-C, with early exposure being associated with a higher risk1. Furthermore, LDL-C fluctuations are associated with ASCVD outcomes2-4. However, the precise mechanisms behind this increased ASCVD risk are not understood. Here we find that early intermittent feeding of mice on a high-cholesterol Western-type diet (WD) accelerates atherosclerosis compared with late continuous exposure to the WD, despite similar cumulative circulating LDL-C levels. We find that early intermittent hyperlipidaemia alters the number and homeostatic phenotype of resident-like arterial macrophages. Macrophage genes with altered expression are enriched for genes linked to human ASCVD in genome-wide association studies. We show that LYVE1+ resident macrophages are atheroprotective, and identify biological pathways related to actin filament organization, of which alteration accelerates atherosclerosis. Using the Young Finns Study, we show that exposure to cholesterol early in life is significantly associated with the incidence and size of carotid atherosclerotic plaques in mid-adulthood. In summary, our results identify early intermittent exposure to cholesterol as a strong determinant of accelerated atherosclerosis, highlighting the importance of optimal control of hyperlipidaemia early in life, and providing insights into the underlying biological mechanisms. This knowledge will be essential to designing effective therapeutic strategies to combat ASCVD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aterosclerose / Dieta Ocidental / Hiperlipidemias / Macrófagos Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aterosclerose / Dieta Ocidental / Hiperlipidemias / Macrófagos Idioma: En Ano de publicação: 2024 Tipo de documento: Article